ABAntonio Alfonso Bencomo-Hernandez

Antonio Alfonso Bencomo-Hernandez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonio Alfonso Bencomo-Hernandez has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predicting Non‐Target Neutrophil Collection During HPC (A): Implications for Research Protocols in Apheresis

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Yendry Ventura‐Carmenate, Shinnette Lumame, Jay Mary Rose‐Roque, Marlene Cato, Hamda Ali, Ruaa Mousa Ali, Rachely Hernandez‐Corrales, Anil Sarode, et al.

    Neutrophils are unintentionally co‐collected during HPC(A) procedures using mononuclear cell collection protocols. Although non‐target granulocyte co‐collection is generally clinically acceptable, excessive neutrophil content may compromise certain translational research applications. This study aimed to develop a predictive model for neutrophil yield during routine HPC(A). A retrospective single‐center analysis of 377 HPC(A) procedures performed between January 2023 and April 2026 was conducted. Donor demographics, hematological parameters, procedural characteristics, and collection efficiency (CE) metrics were analyzed. Correlations between CE 1 and CE 2 were evaluated using Spearman's rank correlation coefficient. A multivariable linear regression model incorporating pre‐apheresis neutrophil count, processed blood volume (pBV), and neutrophil CE 1 was developed to predict neutrophil apheresis yield. Model performance was assessed using R 2 , RMSE, MAE, Bland–Altman analysis, and 5‐fold cross‐validation. Strong positive correlations were observed between CE 1 and CE 2 for both CD34 + cells ( ρ = 0.836, p < 0.0001) and neutrophils ( ρ = 0.865, p < 0.0001). In contrast, the multivariate regression model demonstrated only modest predictive performance for neutrophil yield ( R 2 = 0.198). Compared with the conventional fixed CE 1 approach, the regression‐based model showed lower RMSE, reduced systematic bias, and improved agreement between predicted and observed neutrophil yields on Bland–Altman analysis. Neutrophil yield during HPC(A) can be estimated using a regression model that integrates pre‐apheresis neutrophil count, pBV, and CE 1 . Although predictive performance remains modest, regression‐based approaches improve estimation accuracy compared with simplified fixed CE models and may support procedural planning and translational research applications involving non‐target granulocyte co‐collection in HPC(A) products.

  • Open Access

    Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety Perspective

    by Rene Antonio Rivero-Jimenez, Giselle Rivero-Navea, Dhanya Adukkadukkam, Loubna Abdel Hadi, Fatema M. Al Kaabi, Yendry Ventura-Carmenate, Antonio Alfonso Bencomo-Hernandez

    Chimeric antigen receptor T-cell (CAR-T) therapy represents a transformative yet high-cost immunotherapeutic strategy that has benefited many patients with hematological malignancies and autoimmune diseases. As of January 2025, only a limited number of CAR-T products have received approval by the FDA, EMA, and the NMPA, primarily targeting CD19 or B-cell maturation antigen (BCMA) expressed on cancer cells. The manufacturing of currently approved CAR-T products predominantly relies on lentiviral vectors (LVVs), largely derived from human immunodeficiency virus type 1 (HIV-1). LVVs are favored due to their high transduction efficiency and their ability to stably integrate transgenes into the genomes of both dividing and non-dividing cells, including post-mitotic mammalian cells, an advantage over gamma retroviral vectors, which exhibit limited capacity to transduce non-dividing cells. This review outlines the fundamental biological principles of HIV-derived LVVs, their structure, functional components, and biotechnological applications. It provides a comparative analysis of different viral vectors, an overview of the CAR construct, and a summary of ex vivo CAR-T manufacturing processes. Additionally, emerging in vivo CAR-T approaches are discussed, with reference to clinically approved LVV-based CAR-T products. Emphasis is placed on microbiological perspectives and environmental biosafety. Finally, recent advances in LVV technology are described, providing insight into the production of next-generation CAR-T therapies employing in vivo gene delivery approaches.

  • Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Antonio Alfonso Bencomo‐Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose‐Roque, Marlene Cato, Nameer Al‐Saadawi, Mohamed Ibrahim Abu‐Haleeqa, Aseel Suleiman Alsaid, et al.

    Successful hematopoietic stem cell transplantation relies on the collection of a sufficient number of CD34 + hematopoietic progenitor cells (HPCs). While acid citrate dextrose solution A (ACD‐A) is a common anticoagulant (AC) for HPC apheresis [HPC(A)], recent evidence suggests that concomitant heparin may enhance intra‐apheresis recruitment (IAR) of CD34 + cells and improve collection efficiency. This study aimed to compare citrate‐only and citrate–heparin protocols in routine HPC(A) procedures, with a focus on their effects on IAR and efficiency outcomes. A retrospective analysis was performed on 266 HPC(As) from 193 apheresis donors in autologous and allogeneic settings. Donor demographics, procedural parameters, and collection outcomes were compared between the ACD‐A–only and ACD‐A plus heparin protocols. The study endpoints included apheresis yield (AY/kg), collection efficiencies (CE 1 , CE 2 , and cruCE), recruitment ratio (RR), and performance ratio (PR). Statistical analyses included Mann–Whitney U tests, effect sizes, and partial least squares (PLS) regression. Heparinized procedures demonstrated higher processed total blood volume ratios, lower AC volumes, and superior outcomes across CE 1 (83.8% vs. 72.5%, p = 0.00027), CE 2 (70.8% vs. 64.2%, p = 0.0055), cruCE (77.0% vs. 72.4%, p < 0.0001), RR (2.3 vs. 1.7, p < 0.0001), PR (239.3% vs. 208.2%, p < 0.0001), and AY/kg (6.75 vs. 5.23 × 10 6 CD34 + cells/kg, p = 0.0025). The effect size and PLS analyses confirmed the contribution of heparin as an adjunct AC enhancing multiple apheresis outcomes. In summary, citrate–heparin anticoagulation was found to be a feasible strategy that improved key collection efficiency and IAR metrics during HPC(A).

  • A Practical Method for Inline‐To‐Offline Conversion in Extracorporeal Photopheresis

    by Yandy Marx Castillo‐Aleman, Shinnette Lumame, Charisma Castelo, Jay Mary Rose‐Roque, Marlene Cato, Mutaz Atieh, Michael Onyema, Carlos Agustin Villegas‐Valverde, Antonio Alfonso Bencomo‐Hernandez, Yendry Ventura‐Carmenate

    Extracorporeal photopheresis (ECP) is an established immunomodulatory therapy that is traditionally delivered using either “inline” systems, which integrate mononuclear cell (MNC) collection, photoactivation, and reinfusion, or “offline” platforms that allow greater processing flexibility but require dedicated irradiation equipment. Access to standalone UVA irradiators may be limited in clinical and research settings where cryopreservation of ECP‐treated cells is required. In this study, we describe a practical hybrid approach that adapts the inline Amicus Blue Photopheresis System into an inline‐to‐offline workflow, enabling larger total blood volume processing, partial reinfusion, and cryopreservation of photoactivated MNCs. Using a fixed 200‐mL MNC collection, followed by standard 8‐methoxypsoralen administration and UVA irradiation, 50 mL was reinfused inline, while the remaining product was aliquoted for offline cryopreservation. This method has been implemented in the OPERA clinical trial (NCT05413005) and preserves procedural safety, product integrity, and operational simplicity. In summary, this approach enables offline capabilities within an inline ECP framework without requiring an independent UVA irradiator and expands flexibility for clinical programs and translational research. Trial Registration: NCT05413005.

  • Plasma Separation Efficiency in Double Filtration Plasmapheresis: A Retrospective Study of Patients With Hyperlipidemia

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Shinnette Lumame, Jay Mary Rose‐Roque, Charisma Castelo, Marlene Cato, Maysoon Al‐Karam, Ashwag Shamkhi Al Dhuhaibat, Stefano Benedetti, Fatema Mohammed Al‐Kaabi, et al.

    Background: Double filtration plasmapheresis (DFPP) is a membrane‐based apheresis technique that separates plasma components using two sequential filters; it is commonly used to remove high‐molecular‐weight substances across various indications. While various metrics such as “plasma removal efficiency” are well established in therapeutic plasma exchange, “plasma separation efficiency” (PSE) remains unreported in DFPP. This study aims to evaluate PSE across DFPP sessions performed with plasma filters of different pore sizes. Materials and Methods: A retrospective study of DFPP procedures performed in patients with hyperlipidemia at a single center between April and July 2025 was conducted. Patient demographics, laboratory values, and procedural parameters were collected. PSE was calculated with and without hematocrit (HCT) adjustment (PSE 1 and PSE 2 ). Associations with procedural variables were assessed using paired tests and multivariate linear regression. Results: A total of 42 DFPPs were performed in 19 patients using the Inuspheresis system, alternating two plasma fractionators (DFPP‐1 and DFPP‐2 with large and small pore size, respectively). PSE 2 and PSE 1 declined significantly from DFPP‐1 to DFPP‐2 ( p = 0.0002 and p = 0.0014, respectively), with Cohen's d indicating large and moderate‐to‐large effect sizes. DFPP also resulted in significant reductions in total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), and C‐reactive protein. Multivariate models showed that the plasma separation rate and HCT shifts were significantly associated with PSE 2 and PSE 1 during DFPP‐2 but not during DFPP‐1. Conclusions: PSE is a reproducible parameter influenced by membrane pore size and procedural factors. Incorporating PSE monitoring, particularly with HCT adjustment, may support optimization of individualized DFPP protocols in routine apheresis practice.

  • Open Access

    Validation of an Optimized DuraClone Phenotyping Kit Workflow for TBNK Subset Quantification

    by Carlos Agustin Villegas‐Valverde, Imilla Casado Hernandez, Yaima Zuñiga Rosales, Fatma Abdou, Shadi Sharif Shamat, Antonio Alfonso Bencomo‐Hernandez, Yendry Ventura‐Carmenate

    Quantification of T‐cells, B‐cells, and NK‐cells assay is crucial for diagnosing and monitoring immune diseases and evaluating lymphodepleting therapies. To standardize and validate an optimized workflow of the Beckman Coulter DuraClone IM Phenotyping Basic Kit for quantification of TBNK subsets in peripheral blood. Procedural changes included the use of an alternative lysis buffer, the addition of counting beads, the elimination of centrifugation steps, and an increase in acquisition volume. Validation followed CLSI H42‐A2 and H62 guidelines, assessing accuracy, precision, linearity, and limit of quantification (LLOQ). Accuracy was evaluated by comparison with Immuno‐Trol controls and by Bland–Altman analysis against standard immunophenotyping methods. External proficiency was assessed through participation in the College of American Pathologists (CAP) TBNK program in 2024. Procedural steps were reduced by 50%, and processing time by 38.6%. The modified method demonstrated high accuracy (−3 < bias < 35; cells/μL), a low bias based on Immuno‐Trol targets, and strong agreement in the Bland–Altman analysis. The method successfully passed three CAP external proficiency tests in 2024, confirming interlaboratory reliability. Coefficients of variation for precision were below 10% for all subsets. Linearity exceeded R 2 > 0.99 across clinically relevant ranges. Most subsets demonstrated an LLOQ below 10–50 cells/μL, which is suitable for clinical applications. The proposed modifications to the DuraClone IM kit protocol improved workflow efficiency and analytical performance without compromising accuracy or reproducibility. The validated method provides a standardized, reliable, and time‐efficient alternative for lymphocyte subset quantification.


  • Double Filtration Plasmapheresis for Environmental Toxin Removal: A Case Series of Patients With Hyperlipoproteinemia(a)

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Maysoon Al‐Karam, Shinnette Lumame, Jay Mary Rose‐Roque, Ehab Bawadi, Dina El‐Mouzain, Stefano Benedetti, Yendry Ventura‐Carmenate, Fatema Mohammed Al‐Kaabi, et al.

    Double filtration plasmapheresis (DFPP) is a promising method for removing environmental toxins, but comparative data on toxin‐specific removal patterns remain limited. This study investigates the removal effectiveness of various pollutants in patients with hyperlipoproteinemia(a) undergoing DFPP. We retrospectively analyzed procedures performed using the Inuspheresis System with two filters with differing pore sizes. We assessed the clearance of heavy metals, volatile organic compounds, and organic pollutants by calculating the “ redistribution ratio ” (RR) and the percentage of captured analyte (CA). Analytes with large volumes of distribution and low protein binding, such as toluene, methyl isobutyl ketone, and barium, showed high rebound (RR: 1.95, 1.31, and 1.97, respectively), suggesting redistribution from peripheral compartments. Moderate rebound was observed for partially protein‐bound toxins, including PCB 153 (0.76), PCB 138 (0.74), and hexachlorobenzene (0.66). Low or negative RRs were seen with arsenic (−0.49), mercury (−0.05), and cobalt (0.08), likely reflecting limited redistribution. High CA values were recorded for lipophilic, protein‐bound toxins such as PCBs and p,p′‐DDE. Herein, we demonstrate that DFPP is effective in removing environmental toxins from the human body. The pharmacokinetic properties of each compound are key determinants of DFPP effectiveness and may help guide the development of personalized detoxification strategies to optimize its clinical use.


  • Open Access

    Apoptosis kinetics of purified and PBMC‐associated lymphocytes after photopheresis‐like 8‐methoxypsolaren/UVA treatment

    by Carlos Agustin Villegas‐Valverde, Imilla Casado Hernandez, Yandy Marx Castillo‐Aleman, Gisela Maria Suarez‐Formigo, Amar Riaz, Antonio Alfonso Bencomo‐Hernandez, Yendry Ventura‐Carmenate

    Studies of apoptosis kinetics in extracorporeal photopheresis (ECP) contribute to identifying modifications that can positively impact the configuration of ECP offline in a clinical setting. This work compared for the first time the apoptosis kinetics of human peripheral blood mononuclear cell (PBMC)‐associated T lymphocytes versus the isolation of high‐purity T cells using the MacoGenic G2 system, and times with predictive value were identified through ROC‐AUC analysis, which facilitates quality control of the ECP. PBMC and T lymphocytes from healthy donors were exposed to 300 ng/mL of 8‐methoxypsoralen combined with 2 J/cm 2 of ultraviolet A light (320–400 nm) using the MacoGenic G2 system. The cells were then cultured in vitro , and immunophenotyping and apoptosis induction were assessed by flow cytometry analysis. Apoptosis levels in monocyte controls reached 47% at 24 h, while treated monocytes maintained high apoptosis at 90.4%. Both PBMC‐associated lymphocytes and isolated T cells exhibited sigmoidal apoptosis kinetics; however, PBMCs exhibited a lower apoptosis percentage (65.2%) compared with isolated T cells (73.8%); this difference was not statistically significant ( p = 0.8229). Early apoptosis was faster in NKT, NK, and Tc cells, while B and Th cells exhibited slower kinetics, peaking at 24 h. Isolated T cells showed a faster early apoptosis peak after irradiation (baseline measure), with NKT cells most affected. AUC analysis at 24 h demonstrated high predictive accuracy for apoptosis in PBMCs (AUC = 0.97, p = 0.0004) and isolated T cells (AUC = 1, p = 0.0003). Nearly all treated PBMC‐associated lymphocytes and isolated T lymphocytes underwent apoptosis within 72 h. Apoptosis kinetics were comparable, though slightly accelerated in T lymphocytes. Predictions of ECP effects showed high sensitivity and specificity at 24 h for PBMCs and at 4 h after treatment (baseline) for isolated T lymphocytes, with distinct apoptosis susceptibility patterns.

  • The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC(A) Collections

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Antonio Alfonso Bencomo‐Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose‐Roque, Marlene Cato, Nameer Al‐Saadawi, Mohamed Ibrahim Abu‐Haleeqa, Inas El‐Najjar, et al.

    The hematopoietic progenitor cell apheresis [HPC(A)] is a cornerstone of stem cell transplantation. While multiple apheresis sessions are common in clinical practice, few studies have examined the procedural variability within the same donor across consecutive collections. This study aims to compare changes in the efficiency metrics between the first and second HPC(A) procedures. A retrospective analysis was conducted on paired HPC(A) procedures performed on the same donor between January 2023 and May 2025 at the Abu Dhabi Stem Cells Center. The predefined parameters, including the collection efficiencies (CE1, CE2, cruCE), performance ratio (PR), and total volume processed (TVP), were compared using the Wilcoxon signed‐rank tests. Effect sizes were calculated using Cohen's r, and associations between variables were assessed using the Spearman correlation. Of the 215 procedures screened, 90 met the inclusion criteria. Despite similar preapheresis CD34+ cell counts and flow rates, second‐day procedures demonstrated significantly improved CE1, CE2, and PR, with lower TVP. A large effect size was observed for the TVP/total blood volume (TBV) ratio (r = 0.63), and moderate‐to‐large effect sizes for CE2 (r = 0.41), PR (r = 0.47), and CE1 (r = 0.47). CE1 and CE2 correlated strongly with PR across both sessions, while CE2 correlated positively with TVP/TBV on day 1 (ρ = 0.47) and negatively on day 2 (ρ = −0.40). Second‐day HPC(A) sessions yielded superior efficiency despite reduced volume, supporting the value of individualized collection planning. These “day two advantages” may inform refinements in yield prediction and highlight the need for prospective studies to optimize apheresis strategies.


  • Cell throughput and performance ratio as quality indicators on hematopoietic stem cell apheresis: A single-center experience

    by Yandy Marx Castillo-Aleman, Carlos Agustin Villegas-Valverde, Antonio Alfonso Bencomo-Hernandez, Yendry Ventura-Carmenate, Shinnette Lumame, Charisma Castelo, Nameer Abdul Al-Saadawi, Mohamed Ibrahim Abu-Haleeqa, Inas El-Najjar, Fatema Mohammed Al-Kaabi